NEW YORK – Eli Lilly on Monday said it will acquire in vivo CAR T-cell therapy developer Orna Therapeutics to strengthen its R&D work in genetic medicine and in vivo cell engineering.

Active Genetics (Pro-AG) exploits a naturally created bacterial mating tunnel between cells to inactivate antibiotic resistance.

Jeffrey Epstein reportedly planned to impregnate women at his New Mexico ranch with the aim of "seeding the human race" with his DNA, according to reports, though there is no evidence it was ever ...

Eli Lilly has struck a deal to buy genetic-medicine biotechnology company Orna Therapeutics for up to $2.4 billion in cash.

Jeffrey Epstein corresponded with and funded numerous top scientists, with whom he shared his deranged ideas for improving ...

Combining genetic, structural, and digital innovations can provide an opportunity to develop climate-resilient cereals that ...

New research from the CDCB and the University of Minnesota shows lameness is heritable, opening the door to breeding ...

As a Ph.D. candidate in the Smith School of Chemical and Biomolecular Engineering, Nathan Piligian is developing a novel ...

Drug resistance has accelerated in recent years with the emergence of deadly bacteria and “superbugs.” In response to this ...

By simplifying the engineering process and expanding what can be built, the Golden Gate method greatly broadens the possibilities for scientists working to develop bacteriophages as tools to combat ...

Columnist Michael Le Page delves into a catalogue of hundreds of potentially beneficial gene mutations and variants that is ...

The researchers took a “safety-first” approach. They deliberately excluded all viruses that infect humans or animals from the ...